Skip to main content
Premium Trial:

Request an Annual Quote

Dxcover: Ron Andrews

Glasgow, Scotland-based diagnostics firm Dxcover has named Ron Andrews non-executive chair to support its business operations and long-term goals. He was most recently CEO of Oncocyte. Before that, he held leadership positions at the Bethesda Group, Thermo Fisher Scientific, GE, Roche Diagnostics, Abbott Diagnostics, and other firms. Dxcover is developing liquid biopsy tests for the early detection of multiple cancers and has created a multiomic spectral analysis platform leveraging infrared spectroscopy.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.